SWOG clinical trial number
S1922

Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

78% Accrual
Accrual
78%
Open
Phase
78% Accrual
Accrual
78%
Abbreviated Title
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Activated
12/16/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Gastrointestinal Cancer

Treatment

Irinotecan Leucovorin + 5-FU Ramucirumab Paclitaxel

Reports & Approvals

Trial Locations